Form 4: Rhythm Pharmaceuticals Director Sells Shares Following RSU Vesting

Camille L. Bedrosian, a Director at Rhythm Pharmaceuticals, Inc., disposed of 7,000 common shares on June 18, 2025, following the vesting and conversion of 4,000 restricted stock units.

Summary

• Camille L. Bedrosian, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), reported a transaction on June 18, 2025.
• The transaction involved the exercise or conversion of derivative securities, specifically Restricted Stock Units (RSUs).
• 4,000 shares of common stock were acquired as a result of the full vesting of these RSUs on June 18, 2025.
• Concurrently, 7,000 shares of common stock were disposed of on the same date.
• The RSUs had a conversion price of $0.00 and represented a contingent right to receive one share of common stock per unit.
• Following this transaction, the reporting person holds 0 derivative securities.
• The net effect of these transactions is a reduction of 3,000 common shares in the director's beneficial ownership (7,000 disposed minus 4,000 acquired).

Sentiment

Score: 4

Explanation: The transaction is a routine insider filing involving RSU vesting and a subsequent sale. While the net disposition of shares by a director can be viewed as a slight negative, it's often for tax or personal liquidity reasons and not necessarily indicative of a negative outlook on the company. The limited scope of a Form 4 filing restricts a more definitive sentiment assessment.

Positives

• The vesting of 4,000 Restricted Stock Units indicates a successful milestone for the director's equity compensation plan.

Negatives

• The disposition of 7,000 common shares, which exceeds the 4,000 shares acquired from RSU vesting, results in a net reduction of 3,000 shares in the director's beneficial ownership.
• A net sale by an insider, even if related to compensation, can sometimes be perceived as a lack of confidence or a move to monetize holdings rather than increase exposure to the company's stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves Camille L. Bedrosian, a Director of Rhythm Pharmaceuticals, Inc., making it a related party transaction as per SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders: The net disposition of 3,000 shares by a director could be interpreted by some shareholders as a slight negative signal, though it is a common practice for equity compensation and may not reflect a change in company outlook.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Director Stock Sale, RSU Vesting, Equity Compensation, Camille L. Bedrosian